Lifebit opens Singapore R&D center to advance precision med research in APAC and Japan
Lifebit, a global leader in genomics and health data software, has announced the opening of its new regional operation headquartered in Singapore, marking its expansion into the Asia Pacific and Japan (APJ) region. This move aims to foster collaboration with Synpaxe, Singapore’s national HealthTech agency, to advance precision medicine initiatives across APJ. By leveraging its patented federated technology platform for genomics and biomedical data, Lifebit aims to support crucial precision medicine research in the region.
Dr. Maria Dunford, CEO of Lifebit commented that establishing a regional headquarters in Singapore presents a unique opportunity to address the diverse data needs of healthcare organizations, research institutes, and pharmaceutical companies in the region.
“We are currently integrating our genomic data analytics solution into TRUST to bolster precision medicine research in Singapore and the wider APJ region,” Dunford added. “We eagerly anticipate collaborating with organizations that share our commitment to pushing the boundaries of genomics and precision medicine.”
Andy Ta, Chief Data Officer and Director of Data Analytics & AI at Synpaxe, echoed this sentiment, saying that the company’s partnership with Lifebit enables advancing research and clinical insights using clinico-genomic data for precision medicine. “Our goal is to expedite the translation of these insights into clinical workflows, thereby significantly enhancing healthcare for Singaporeans,” Ta said.
Singapore’s direction to fostering precision medicine research and innovation, supported by robust governmental initiatives utilizing genomic and clinical data, makes it a standout market in Asia. Lifebit’s establishment of an R&D center in Singapore is expected to actively contribute to recent collaborations within the APJ region.
Lifebit’s mission is to ensure that access to biomedical data is never again an obstacle to curing diseases. Its expansion into APJ builds upon its growth, with recent partnerships announced in the US, Central and South America, and Europe over the past 12 months.
In 2022, Lifebit raised a US$60 million Series B funding round, led by global investment firm Tiger Global Management. Its pioneering technology enables vital biomedical data to be found and used within a highly secure research environment. Lifebit’s suite of AI-powered, end-to-end federated software solutions facilitates faster data insights, accelerates drug discovery pipelines, and enhances the success of clinical trial interpretations. (Press Release)
Category: Features, Technology & Devices
Subscribe
If you enjoyed this article, subscribe to receive more just like it.
